Phaseline

Companies › Arthrosi Therapeutics

Arthrosi Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XOI High Dose
Xanthine oxidase inhibitor
XDHPhase 3GoutNov 2026
XOI Low Dose
Xanthine oxidase inhibitor
XDHPhase 2GoutNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06846515XOI High DosePhase 3GoutImmunologyAug 2026
NCT07116746XOI Low DosePhase 2GoutImmunologyNov 2026
NCT07116746XOI High DosePhase 2GoutImmunologyNov 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

XDH (2)

Companies with the same targets

Shenyang Sunshine Pharmaceutical Shanghai Institute Of Biological Products Innovent Biologics Technology Limited (Shanghai R&D Center)

Companies built like this

Paradigm Biopharmaceuticals Triveni Bio Hangzhou Highlightll Pharmaceutical Integrative Skin Science and Research MRM Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.